0
20. 5. 2016.
Defining the mechanisms of response and resistance to anti-PD-1 therapy: An exploratory phase II study of pembrolizumab in advanced melanoma (ADAPTeM).
TPS9599Background: Several large-scale clinical trials of pembrolizumab have demonstrated substantial efficacy and survival benefit in metastatic melanoma (MM). However, responses are limited to a ...